Related references
Note: Only part of the references are listed.Bicyclic triterpenoid Iripallidal induces apoptosis and inhibits Akt/mTOR pathway in glioma cells
Nitin Koul et al.
BMC CANCER (2010)
Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2
Ker Yu et al.
CANCER RESEARCH (2010)
Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival
Sean M. McBride et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor
Janine Masri et al.
CANCER RESEARCH (2007)
Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis
Hendrik Seeliger et al.
CANCER AND METASTASIS REVIEWS (2007)
Molecularly targeted therapies for malignant gliomas: advances and challenges
Marto Penas-Prodo et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling
Markus J. Riemenschneider et al.
CANCER RESEARCH (2006)
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Reuben J. Shaw et al.
NATURE (2006)
mTOR promotes urvival and astrocytic characteristics induced by Pten/Akt signaling in glioblastoma
XY Hu et al.
NEOPLASIA (2005)
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
K Inoki et al.
NATURE CELL BIOLOGY (2002)
Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice
EC Holland et al.
NATURE GENETICS (2000)